Results 71 to 80 of about 463,492 (156)

Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel

Internal Medicine Journal, EarlyView.
Abstract Chronic kidney disease (CKD) and cardiovascular disease (CVD) are major causes of morbidity and mortality in people with type 2 diabetes (T2D). Contemporary CKD guidelines increasingly support incorporation of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) as an additional pillar of cardiorenal therapy alongside renin–angiotensin ...
Eugenia Pedagogos, Roger Chen, Adam Nelson, Sunil Badve, Roy Rasalam, Richard MacIsaac   +5 more
wiley   +1 more source

First‐in‐human trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of zagociguat (CY6463), a CNS‐penetrant soluble guanylyl cyclase stimulator

Clinical and Translational Science, 2023
Soluble guanylate cyclase (sGC) and its product, cyclic guanosine monophosphate, play a role in learning and memory formation. Zagociguat (CY6463) is a novel stimulator of sGC being developed for the treatment of neurodegenerative disease.
Sebastiaan J. W. vanKraaij, Pim Gal, Laura G. J. M. Borghans, Erica S. Klaassen, Francis Dijkstra, Christopher Winrow, Chad Glasser, Geert Jan Groeneveld   +7 more
doaj   +1 more source

Cerebrovascular flow‐mediated dilation in humans: Methodological challenges, physiological interpretation and future integrations

Experimental Physiology, EarlyView.
Abstract Arterial shear‐mediated vasodilation is a well‐established measure of endothelial function and serves as a critical biomarker for cardiovascular disease risk. Endothelial function can be measured using a variety of experimental methodologies; however, the most widely adopted technique is ultrasound‐based flow‐mediated dilation (FMD), in which ...
Yi Zhen Bao, Tabitha V. Craig, Jenna C. McCrone, Kurt J. Smith, Michael M. Tymko   +4 more
wiley   +1 more source

Phototherapy Strategies for Cancer Treatment: Mechanisms and Emerging Nanomaterials

Aggregate, Volume 7, Issue 10, October 2026.
Phototherapy offers spatiotemporally controlled cancer treatment by converting light into heat, reactive oxygen species, immune activation, and therapeutic gas release. This review summarizes the mechanisms and emerging nanomaterials for photothermal therapy, photodynamic therapy, photoimmunotherapy, and photo‐gas therapy, emphasizing structure ...
Fan Liu, Jun Huang
wiley   +1 more source

Dinâmica da guanilato ciclase solúvel na sepse: uma janela de oportunidade [PDF]

, 2006
Tese (doutorado) - Universidade Federal de Santa Catarina, Centro de Ciências Biológicas. Programa de Pós-Graduação em Farmacologia.A alta produção de óxido nítrico (NO) é um dos principais responsáveis pela hipotensão e hiporeatividade a ...
Fernandes, Daniel
core  

The primary structure of the 70 kDa subunit of bovine soluble guanylate cyclase [PDF]

, 1988
The primary structure of the 70 kDa subunit of soluble bovine guanylate cyclase, which catalyzes the formation of cyclic GMP from GTP, has been determined. The alignment of six different clones out of two bovine libraries yielded a total of 3.1 kb with a
Herz, Joachim, Niroomand, Feraydoon, Eycke Böhme, Klaus-Dieter Hinsch, Gausepohl, Heinrich, Günter Schultz, Doris Koesling, Rainer Frank, Mülsch, Alexander, Feraydoon Niroomand, Heinrich Gausepohl, Frank, Rainer, Schultz, Günter, Koesling, Doris, Böhme, Eycke, Alexander Mülsch, Joachim Herz, Hinsch, Klaus-Dieter   +17 more
core   +1 more source

Development of a population pharmacokinetic model using combined paediatric and adult data for four pulmonary arterial hypertension drugs

British Journal of Clinical Pharmacology, Volume 92, Issue 10, Page 3611-3621, October 2026.
Aims Pulmonary arterial hypertension (PAH) is a syndrome characterized by elevated pulmonary artery pressure. We developed a population pharmacokinetic (PPK) model using combined plasma drug concentration data from Japanese paediatric (<15 years) and adult (≥15 years) patients with PAH to investigate the pharmacokinetic characteristics of PAH ...
Motoyasu Miura, Shimako Tanaka, Ririka Aihara, Shun Yamamoto, Yasumi Nakashima, Yasuharu Kashiwagura, Akio Hakamata, Sachiko Miyakawa, Mariko Tatsuguchi, Keiichi Odagiri, Noriyuki Namiki, Naoki Inui, Hiroshi Watanabe, Shinya Uchida   +13 more
wiley   +1 more source

Olinciguat, an Oral sGC Stimulator, Exhibits Diverse Pharmacology Across Preclinical Models of Cardiovascular, Metabolic, Renal, and Inflammatory Disease

Frontiers in Pharmacology, 2020
Nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic 3',5' GMP (cGMP) signaling plays a central role in regulation of diverse processes including smooth muscle relaxation, inflammation, and fibrosis.
Daniel P. Zimmer, Courtney M. Shea, Jenny V. Tobin, Boris Tchernychev, Peter Germano, Kristie Sykes, Ali R. Banijamali, Sarah Jacobson, Sylvie G. Bernier, Renee Sarno, Andrew Carvalho, Yueh-tyng Chien, Regina Graul, Emmanuel S. Buys, Juli E. Jones, James D. Wakefield, Gavrielle M. Price, Jennifer G. Chickering, G. Todd Milne, Mark G. Currie, Jaime L. Masferrer   +20 more
doaj   +1 more source

Lung‐Cardiovascular Interactions and Derangements in ARDS

Comprehensive Physiology, Volume 16, Issue 5, October 2026.
This review proposes an anatomical near‐ and far‐field framework for lung‐cardiovascular interactions in ARDS. Grounded in pathological and biological studies, the evidence spans pulmonary vascular, right ventricular, and systemic endothelial derangements and reviews available evidence for targeted therapies.
Pablo A. Sanchez, Connor O'Brien, Matthieu Legrand, Carolyn S. Calfee, Michael A. Matthay   +4 more
wiley   +1 more source

Drugs targeting the NO-sGC-cGMP pathway in the treatment of patients with COPD-associated pulmonary hypertension: a systematic review

Frontiers in Pharmacology
BackgroundPulmonary hypertension (PH) due to chronic obstructive pulmonary disease (COPD) is categorized as group 3 PH and is associated with increased mortality and morbidity. Currently, there are no approved therapies for those who have PH secondary to
Abdullah A. Alqarni, Abdullah A. Alqarni, Sara A. Alghamdi, Abdulelah M. Aldhahir, Jaber S. Alqahtani, Rayan A. Siraj, Ahmed H. Alasimi, Heba M. Bintalib, Heba M. Bintalib, Abdulkareem A. AlGarni, Abdulkareem A. AlGarni, Mansour Majrshi, Mansour Majrshi, Mansour Majrshi, Adel M. Alshabasy, Salma AlBahrani, Salma AlBahrani, Hassan Alwafi   +17 more
doaj   +1 more source